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MEG2, a protein tyrosine phosphatase with a unique NH
 
2
 
-terminal lipid-binding domain, 
binds to and is modulated by the polyphosphoinositides PI
 
(4,5)
 
P
 
2
 
 and PI
 
(3,4,5)
 
P
 
3
 
. Recent data 
implicate MEG2 in vesicle fusion events in leukocytes. Through the genesis of Meg2-deficient 
mice, we demonstrate that Meg2
 
    
 
embryos manifest hemorrhages, neural tube defects 
including exencephaly and meningomyeloceles, cerebral infarctions, abnormal bone 
development, and 
 
 
 
90% late embryonic lethality. T lymphocytes and platelets isolated 
from recombination activating gene 2
 
   
 
 mice transplanted with Meg2
 
   
 
 embryonic liver–
derived hematopoietic progenitor cells showed profound defects in activation that, in T 
lymphocytes, was attributable to impaired interleukin 2 secretion. Ultrastructural analysis of 
these lymphocytes revealed near complete absence of mature secretory vesicles. Taken 
together, these observations suggest that MEG2-mediated modulation of secretory vesicle 
genesis and function plays an essential role in neural tube, vascular, and bone development 
as well as activation of mature platelets and lymphocytes.
 
Tyrosine phosphorylation is pivotal in diverse
physiological processes in eukaryotes, including
cell proliferation and differentiation, cell–cell
communication, and regulation of transmem-
brane and intracellular signaling pathways (1,
2). Protein tyrosine phosphorylation reflects
the balance between the activities of protein
tyrosine kinases and protein tyrosine phos-
phatases (PTPs). The latter selectively remove
phosphate from tyrosine residues, an outcome
that can negatively or positively regulate sig-
naling pathways. Recent estimates suggest that
the human genome contains at least 107 PTP
genes, remarkably similar to the number of
tyrosine kinases (3, 4). However, by comparison
with protein tyrosine kinases, relatively little is
known about the specific functions of the
majority of PTPs.
MEG2, also known as PTPN9, was origi-
nally cloned from a megakaryocytic cell line
and is distinguished from other mammalian
PTPs by virtue of an NH
 
2
 
-terminal lipid-binding
domain with homology to yeast Sec14p that
binds to and is activated by polyphospho-
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Abbreviations used: ES, embry-
onic stem; NSF, 
 
N
 
-ethylmale-
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membrane protein. 
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inositides PIP
 
2
 
 and PIP
 
3
 
 as well as by phosphatidyl serine
(5–10). We have recently reported that MEG2 resides on in-
ternal membranes, including secretory vesicles and granules
in neutrophils and lymphocytes, and regulates secretory vesi-
cle size and fusion via dephosphorylation of a key vesicle
fusion protein, 
 
N
 
-ethylmaleimide sensitive factor (NSF),
which is involved in the disassembly of cis complexes of sol-
uble NSF attachment protein receptor (SNARE) proteins
under ATP hydrolysis (6, 7, 11).
To investigate the functional importance of MEG2 in
development and in hematopoietic cell function, we gener-
ated mice deficient in MEG2 by homologous recombina-
tion. Meg2
 
 
 
/
 
 
 
 embryos displayed multiple neurodevel-
opmental defects and hemorrhages as well as 
 
 
 
90% late
embryonic lethality. Lymphocytes and platelets from mice
transplanted with Meg2
 
 
 
/
 
 
 
 embryonic liver–derived he-
matopoietic progenitor cells demonstrated severe functional
defects reflecting anomalous agonist-induced secretion.
 
RESULTS
 
To characterize the genomic organization of murine Meg2,
we isolated a BAC clone containing the full-length Meg2
gene and sequenced it. By comparison of the genomic se-
quence with the cDNA sequence, we deduced that Meg2
comprises 13 exons, with the catalytic domain encoded
by exons 8–13 (Fig. 1 A). During embryogenesis, Meg2
mRNA expression was detected as early as embryonic day 9
(E9) and persisted throughout the embryonic period as as-
sessed by northern analysis (Fig. 1 B). In adult mice, Meg2
mRNA was widely expressed with the highest concentra-
Figure 1. Confirmation of null Meg2 allele in Meg2 /  mice. 
(A) Genomic organization of murine Meg2 illustrating introns and exons. 
H, HindIII. The long dashed lines represent HindIII restriction sites. The 
short lines and black boxes represent exons. Exon1  is an exon that exists 
only in an alternatively spliced transcript characterized by RT-PCR and 
RACE. The size and location of the exons were determined by comparison 
of the sequences of full-length cDNA and genomic cDNA. The genomic 
size of Meg2 is  67 kb. The bar represents 10 kb. (B) Northern blots from 
embryos and adult mice. Embryo and tissue northern analysis demonstrating 
Meg2 mRNA expression in different tissues and during embryogenesis. 
FirstChoice Northern Blot Mouse Blot I was hybridized with a mouse Meg2 
full-length cDNA probe and reprobed with human  -actin. He, heart; 
Br, brain; Li, liver; Sp, spleen; Ki, kidney; E, embryo; Lu, lung; Te, testis. 
(C) Gene targeting strategy. The wild-type Meg2 locus and the targeted 
allele after ES cell homologous recombination are illustrated. The deleted 
region of genomic DNA in the targeted allele contains exons 10, 11, 12, 
and part of exon 13. R, RcaI; P, PstI; B, BamHI; S, StuI; Neo, neomycin-
resistance element cassette. Bar, 1 kb. The black rectangles represent the 
probes used for the genotyping of ES cells and mice by Southern hybrid-
ization. (D) Genotyping of Meg2 / , Meg2 / , and Meg2 /  mice by 
multiplex PCR. The 2.0- and 1.7-kb bands correspond to the wild-type and 
targeted alleles, respectively. (E) Southern analysis of tail DNA from wild-
type ( / ) mice and mice containing the targeted (null) allele ( /  
heterozygote). Genomic DNA was digested with RcaI or StuI and probed 
with 5  or 3  probe individually. (F) Northern analysis of Meg2  / , Meg2 / , 
and Meg2 /  embryos at day E15. PolyA  RNA from embryos was probed 
with a murine Meg2 full-length cDNA probe. The blots were subsequently 
reprobed with a human  -actin RNA probe. The 3.9-kb band corresponds 
to the major Meg2 transcript. The uniform density of the actin bands confirm 
equal loading of PolyA  RNA. (G) Western blots of tissues from the liver, 
lung, and brain of Meg2 / , Meg2 / , and Meg2 /  mice demonstrating 
the absence of detectable MEG2 protein in tissues from the Meg2 /  mice, 
confirming a null mutation. 
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tions in the brain, lung, heart, liver, kidneys, and testes and
lower levels of expression in the spleen and bone marrow
(Fig. 1 B). The predominant mRNA species was a 3.9-kb
transcript present in all tissues examined. However, alterna-
tive transcripts of lower abundance were noted in several tis-
sues, including the liver, brain, and testes, that were attribut-
able to alternative mRNA splicing.
To ascertain the functional importance of Meg2, we
generated Meg2-deficient mice by homologous recombina-
tion in embryonic stem (ES) cells targeting exons 10–13
containing part of the catalytic domain (Fig. 1, C–E). Mice
heterozygous for Meg2 (Meg2
 
 
 
/
 
 
 
) appeared healthy and
were fertile. At day (E12), Mendelian ratios of Meg2
 
 
 
/
 
 
 
,
Meg2
 
 
 
/
 
 
 
, and Meg2
 
 
 
/
 
 
 
 (1:2:1, respectively) embryos were
detected. However, there was a decrease in the fraction of
Meg2
 
 
 
/
 
 
 
 homozygous embryos between days E15 and
birth, with 
 
 
 
10% of Meg2
 
 
 
/
 
 
 
 embryos surviving to birth
and the immediate postnatal period. Of the live-born
Meg2
 
 
 
/
 
 
 
 pups, all were severely runted and very few sur-
vived to weaning. Meg2
 
 
 
/
 
 
 
 embryos and pups did not ex-
press Meg2 RNA or protein as determined by northern and
western analysis, respectively (Fig. 1, F and G), confirming
that these mice carry a null Meg2 allele.
 
MEG2
 
    
 
mice display craniofacial and neurodevelopmental 
abnormalities and hemorrhages
 
As early as day E10, Meg2
 
 
 
/
 
 
 
 embryos demonstrated growth
retardation and evidence of neural tube defects, including
craniofacial abnormalities (shortened snout and domed cra-
nium), exencephaly, encephaloceles, and meningomyelo-
celes (Fig. 2 A) that were also apparent in the few live-born
pups (Fig. 2 B). The brains of neonatal Meg2
 
 
 
/
 
 
 
mice were
grossly smaller than Meg2
 
 
 
/
 
 
 
 or Meg2
 
 
 
/
 
 
 
 littermates, and
histological analysis revealed areas of colliquative necrosis
containing foamy and debris-laden macrophages (Fig. 2, C
and D). Within such areas, there was petechial hemorrhage
containing macrophages with ingested erythrocytes (Fig. 2
D), indicating that the hemorrhage occurred before death.
The areas of necrosis involved the cerebral cortex and sub-
cortical white matter. The adjacent lateral ventricles were
enlarged, and the white matter demonstrated rarefaction and
microcystic changes. These alterations are consistent with ei-
ther a primary endothelial defect or with impaired platelet
function (vide infra) that may enhance a bleeding tendency
by impairment of hemostatic plug formation. Of the few
Meg2
 
 
 
/
 
 
 
 mice surviving past weaning, several demonstrated
a conspicuous tremor and paraparesis, the latter likely due to
spinal meningomyeloceles.
Most Meg2
 
 
 
/
 
 
 
 embryos demonstrated large areas of
hemorrhage in the craniofacial and cervical regions as well as
dorsal aspects of the trunk (Fig. 2 A). Meg2
 
 
 
/
 
 
 
 embryos also
demonstrated abnormalities of calvarial and long bone for-
mation. Meg2
 
 
 
/
 
 
 
 embryos and newborn pups had absent
calcification of the cranium as well as thinning and deficient
calcification of the diaphyseal portion of the long bones (Fig.
3). Development of the other major organs, including the
heart, lungs, kidneys, and liver, was grossly normal in Meg2
 
 
 
/
 
 
 
embryos, and histological analysis of these organs did not re-
veal any abnormalities.
Death of Meg2
 
 
 
/
 
 
 
 embryos during late embryogenesis
was likely attributable to hemorrhage into the cranial and
dorsal areas and/or to severe neural tube closure defects.
The vast majority of late embryonic and live-born Meg2
 
 
 
/
 
 
 
mice demonstrated obvious craniofacial malformations, in-
cluding abnormal dentition and cleft palate, doming of
the cranium, and shortened snout, and all were severely
runted (Fig. 2 B). In the immediate perinatal period, serum
electrolytes, glucose, calcium, creatinine, urea nitrogen,
and albumin, and liver enzymes were within normal limits
in surviving Meg2
 
 
 
/
 
 
 
 mice. Most of these mice had dif-
ficulty feeding that was attributable to the facial, dental,
and neurological abnormalities. Most did not survive until
Figure 2. Neural tube developmental defects and cerebral infarctions 
in Meg2 /  mice. (A) Whole mount views of Meg2 /  embryos showing 
exencephaly, craniofacial maldevelopment, meningomyeloceles, and hem-
orrhages. (B) Photographs of wild-type (Meg2 / ) and Meg2 /  newborn 
pups showing domed heads, hemorrhages, and runting in the Meg2 /  
pups. (C) Low power view (15 ) of histology of brain tissue showing 
cerebral hemorrhagic infarction. H indicates the areas of hemorrhagic 
infarction, and V indicates dilation of the adjacent lateral ventricle. 
(D) Higher power view (200 ) of histology of brain tissue showing 
cerebral hemorrhagic infarction. Arrows denote the area of infarction.PTP-MEG2 MODULATES SECRETORY VESICLE FUNCTION | Wang et al. 1590
weaning despite attempts at liquid nutritional supplemen-
tation. Taken together, these observations indicate that
MEG2 is required for normal embryonic development, in-
cluding neural tube formation as well as bone and dental
development.
Meg2 deficiency results in defective platelet and 
lymphocyte function
Next, we examined the role of MEG2 in hematopoietic cell
function. The high degree of lethality in Meg2 /  mice and
their sickly condition leading to premature death in the neo-
natal period precluded reliable analysis of hematopoietic cell
function in these mice. Accordingly, we transplanted he-
matopoietic progenitor cells from the livers of day E15.5
Meg2 /  and Meg2 /  embryos into lethally irradiated
Rag2 /  mice (12). Mice transplanted with Meg2 /  he-
matopoietic progenitor cells demonstrated normal numbers
and morphology of peripheral blood leukocytes, red blood
cells, and platelets. Neutrophils from these mice were mor-
phologically normal and displayed levels of GR-1 (Ly6G)
comparable to their wild-type controls as assessed by flow
cytometry. Functional analysis of Meg2 /  neutrophils, in-
cluding surface expression of CD11b, adhesion to serum-
coated tissue culture plastic, and activation of the NADPH
oxidase, did not reveal any abnormalities (Table I).
By contrast, Meg2 /  platelets and lymphocytes dem-
onstrated significant functional abnormalities. Thrombin-
induced platelet aggregation was considerably diminished in
Meg2 /  compared with Meg2 /  platelets (Fig. 4). By
comparison, ADP-induced aggregation was only slightly im-
paired in Meg2 /  platelets. These observations are consis-
tent with defective release of platelet granules in Meg2 / 
platelets, a process that is involved in the second phase of
platelet aggregation (13, 14).
Although lymphocyte development and maturation was
normal in mice transplanted with Meg2 /  hematopoietic
progenitor cells (Table II and Fig. 5), their function was se-
verely compromised. Proliferation of Meg2 /  T lympho-
cytes (both from the thymus and peripheral lymph nodes)
was deficient in response to receptor-dependent (anti-CD3,
CD3 plus anti-CD28 antibodies, and Con A) or -indepen-
dent (PMA plus ionomycin) stimulation (Fig. 6). The defect
in T lymphocyte activation was likely related, in part, to
suboptimal IL-2 secretion because the amount of secreted
IL-2 was substantially diminished from Meg2 /  lympho-
cytes (Fig. 6 C). This defect could not be explained by
alterations in the surface expression of IL-2 receptors as
CD25 expression was normal in Meg2 /  lymphocytes
(Fig. 6 D). Importantly, supplementation (“rescue”) of
Figure 3. Abnormal formation of calvarial and long bones in 
Meg2 /  mice. X-ray (FAXetron) images showing calvarial and long bone 
abnormalities of young Meg2 /  (A and C) Meg2 /  (B and D) pups.
Table I. Analysis of neutrophils from Meg2 /  and Meg2 /  hematopoietic progenitor cell–transplanted mice
Parameter Meg2 /  Meg2 / 
GR-1 fluorescence (RFU) 12.4   1.4 12.4   1.7
Dihydrorhodamine fluorescence (RFU) (unstimulated cells) 76.6   5.88 71.9   8.0
Dihydrorhodamine fluorescence (PMA stimulation) 140.9   23.59 148.18   10.30
CD11b fluorescence (RFU) (unstimulated cells) 93.3   15.0 86.19   6.2
CD11b fluorescence (RFU) (PMA stimulation) 269.3   75.8 312.2  46.5
% Adhesion (unstimulated cells) 8.9   1.6 10.4   1.6
% Adhesion (PMA stimulation) 14.6   1.6 14.3   1.5
Data are presented as relative fluorescence units (RFU) as assessed by flow cytometry or as percent adhesion.JEM VOL. 202, December 5, 2005 1591
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Meg2 /  lymphocytes with exogenous IL-2 restored their
proliferative capacity to both receptor-dependent and -in-
dependent stimulation (Fig. 6 E), providing strong evidence
that the primary defect in Meg2 /  lymphocytes is related
to IL-2 secretion. In support of this notion, intracellular
levels of IL-2 were normal (Fig. 6 F), indicating that the
primary defect is attributable to abnormal agonist-regulated
exocytosis (secretion) of IL-2. A defect in agonist-induced
secretion was observed with other cytokines, such as GM-
CSF, IFN- , and IL-6, but was not universal because secre-
tion of TNF- , IL-5, IL-10, and IL-12 were largely unaf-
fected (Table III).
To determine the ultrastructural basis for this defect, T
lymphocytes were examined by electron microscopy. These
studies revealed that the number of secretory vesicles was
markedly diminished in Meg2 /  compared with Meg2 / 
lymphocytes (Fig. 7). Moreover, the Meg2 /  lymphocytes
displayed nonmembrane-bound collections of electron dense
particles with a “cluster-of-grapes” appearance. These clus-
ters of particles may represent failed attempts to fuse small
transport vesicles into immature secretory vesicles, which
normally is the first step in the biogenesis of mature secre-
tory vesicles.
DISCUSSION
Our studies demonstrate the fundamental role played by
MEG2 in diverse aspects of murine embryonic development
and in the function of mature cells of hematopoietic origin.
Meg2 /  T lymphocytes and platelets demonstrated pro-
found defects in activation. Importantly, the common mech-
anism responsible for this anomalous function is faulty ago-
nist-induced secretion (exocytosis). In T lymphocytes, this
was manifest by diminished IL-2 secretion and correlated
Figure 4. Abnormal platelet function in Meg2 /  mice. (A) Images of 
platelet aggregates in response to ADP and thrombin. (a and b) Platelet-
rich plasma from Meg2 /  (a) and Meg2 /  (b) hematopoietic progenitor 
cell–transplanted mice was treated with 20  M ADP. (c and d) Washed 
platelets from Meg2 /  (c) and Meg2 /  (d) hematopoietic progenitor 
cell–transplanted mice were treated with 1 U/ml thrombin. (d) Note that 
the platelet aggregates from wild-type hematopoietic progenitor cell–
transplanted mice are substantially larger than those derived from Meg2 /  
mice. (B) Platelet aggregometry traces in response to thrombin and ADP. 
Left panel: platelet-rich plasma from Meg2 /  (black trace) and Meg2 /  
(gray trace) hematopoietic progenitor cell–transplanted mice was treated 
with thrombin to induce platelet aggregation. Platelet aggregation was 
measured by aggregometry after stimulation with 1 U/ml thrombin. Note 
the decreased thrombin-induced platelet aggregation in Meg2 /  platelets. 
Right panel: Washed platelets from Meg2 /  (black trace) and Meg2 /  
(gray trace) hematopoietic progenitor cell–transplanted mice (black trace) 
were treated with 20  M ADP. Meg2 /  platelets demonstrate diminished 
platelet aggregation compared with Meg2 /  platelets.
Table II. Immune cell numbers in Meg2 /  and Meg2 /  
hematopoietic progenitor cell–transplanted mice
Immune organ Cell number
Meg2    Meg2   
Thymus 1.98   108 2.23   108
Lymph Node 5.5   107 4.2   107
Spleen 9.57   108 10.12   108PTP-MEG2 MODULATES SECRETORY VESICLE FUNCTION | Wang et al. 1592
with the absence of mature secretory vesicles as assessed by
electron microscopy. These vesicles are known to contain
IL-2, and their fusion with the plasma membrane is required
for agonist-induced extracellular secretion of the cytokine
(7, 11). These data confirm and extend our previous obser-
vations in human Jurkat T lymphoma cells where overex-
pression of functional MEG2 resulted in enlarged vesicles
and, conversely, expression of catalytically inactive MEG2
prevented the formation of mature vesicles and abrogated
agonist-induced IL-2 secretion (11). The absence of mature
secretory vesicles in Meg2 /  T lymphocytes underscores
the importance of MEG2 in the biogenesis of these crucial
components of the exocytic apparatus.
The functional defect in the second phase of thrombin-
induced aggregation observed in Meg2 /  platelets is also
likely attributable to defective agonist-induced secretion be-
cause this phase of aggregation is dependent on the exocyto-
sis of granule-associated proteins, mediators, and adhesion
molecules (13, 14). By comparison, the early phase of plate-
let aggregation that is dependent on integrin GPIIb/IIIa–
fibrinogen interaction is preserved in the Meg2 /  platelets.
Taken together, these observations reveal the importance of
MEG2 in the function of cells of hematopoietic origin that
involve regulated secretion.
Our observations point to a fundamental role for MEG2
in regulated secretion, a complex process involving biogene-
sis and fusion of the vesicle membranes with the plasma
membrane followed by release of the vesicular contents.
SNARE proteins are key participants in these events (15–
17). A common feature of these proteins is the SNARE mo-
tif, which can self-assemble into a four-helix bundle (17).
When this pairing occurs in trans, between v (or R)-
SNAREs from a vesicle and t (or Q)-SNAREs from a target
compartment, membrane fusion proceeds. Vesicle fusion in-
volves a cascade of molecular events, beginning with a prim-
ing stage that is followed by docking with target membranes
and the development of the fusion pore (18, 19). The key
reaction in the priming stage is the dissociation of cis–
SNARE complexes by NSF, a cytosolic protein that regu-
lates membrane fusion by disassembling cis complexes of
SNARE proteins under ATP hydrolysis. Importantly, we
have recently reported that NSF is a substrate for MEG2
(11). Disassembly of cis complexes of SNARE proteins is
critical for formation of a multimeric trans complex at the
site of contact between fusion partners and for recycling of
the proteins for subsequent rounds of fusion (20, 21). Null
mutants of NSF are lethal in yeast and Drosophila, consistent
with its obligatory role in general membrane fusion (22–24).
The ATPase activity of NSF is enhanced by  -soluble NSF
attachment protein (SNAP), which mediates NSF binding to
SNARE complexes with other factors (25, 26). NSF is pro-
posed to bind directly to syntaxin and SNAP-25 in a com-
Figure 5. Normal development of lymphoid cell populations in 
Meg2 /  mice. Flow cytometric analysis of lymphocytes from the (A) 
spleen, (B) thymus, (C) bone marrow, and (D) lymph nodes from Rag2 /  
mice transplanted with Meg2 /  and Meg2 /  embryonic liver–derived 
hematopoietic progenitor cells.
Table III. Cytokine production by Meg2 /  and Meg2 /  peripheral lymphocytes
Stimulus Control Anti-CD3 Anti-CD3   CD28 Con A PMA   Ionomycin
Meg2 Genotype                                        
GM-CSF 43 35 151 82 194 92 84 71 191 90
IFN-  nd nd 356 87 451 121 nd 62 141 124
TNF-  nd nd 56 35 62 31 4 26 47 32
IL-1  nd nd nd nd nd nd nd nd nd nd
IL-4 nd nd 100 43 129 49 nd 19 31 37
IL-5 nd nd 89 41 117 30 10 nd 18 64
IL-6 9 9 761 306 1,042 360 51 231 401 376
IL-10 9 9 74 37 71 44 13 34 23 34
IL-12 (p70) 9 8 13 11 13 10 9 10 12 11
Data represent extracellular cytokine levels in pg/ml as assessed by a bead binding array. n.d., none detected (below limits of detection). These results are representative of two 
separate experiments performed in duplicate.JEM VOL. 202, December 5, 2005 1593
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plex with vesicle-associated membrane protein (VAMP; ref-
erences 21 and 23). Although NSF is required for virtually
all membrane fusion events, its participation in agonist-stim-
ulated secretion might be accounted for by changes in activ-
ity and/or subcellular distribution. In this regard, recent evi-
dence from us and others indicates that posttranslational
modification of NSF, via reversible phosphorylation of
tyrosine 83 or nitrosylation, alters its capacity to facilitate
membrane fusion (11, 27). This provides a plausible mecha-
nism for involvement of NSF in regulated secretion and a
role for MEG2 in these events.
Regulated (agonist-induced) secretion is pivotal for leu-
kocyte function in immune responses (28, 29). For example,
during T lymphocyte activation, IL-2 is secreted and binds to
its receptor, triggering a cascade of intracellular events in-
volved in cell activation and proliferation (30). To facilitate
secretion, lymphocytes express a variety of SNARE proteins,
such as syntaxin 11 and SNAP-23 (27, 28, 31). In addition to
classical secretion (exocytosis), SNARE proteins are also in-
volved in internalization and recycling of TCRs, events that
are crucial during interaction with APCs. During this interac-
tion, TCRs accumulate at the immunological synapse (the
site of T cell–APC contact) by a mechanism that involves po-
larized recycling of the TCR in recycling endosomes medi-
ated by exocytic SNARE proteins and presumably NSF (28).
Interference with SNARE function reduces TCR accumula-
tion at this site and impedes T cell activation (28).
Agonist-induced secretion in other leukocyte types also
involves SNARE proteins. For example, platelets are known
to express multiple SNARE proteins, including cellubrevin,
SNAP-23 and SNAP-25, and syntaxin-2 and syntaxin-4, as
well as VAMP-3 and VAMP-8, and interference with their
function abolishes exocytosis from platelet  , dense, and lyso-
somal granules (32–37). Myeloid cells, such as neutrophils, also
Figure 6. Defective activation in Meg2 /  T lymphocytes. (A) Thymus-
derived T lymphocyte proliferation in response to agonist stimulation as 
assessed by [3H]thymidine uptake. Thymus-derived lymphocytes from 
Rag2 /  mice transplanted with Meg2 /  (wild- type) and Meg2 /  
hematopoietic progenitor cells were activated with either TCR-mediated 
stimuli (anti-CD3 or anti-CD3 plus anti-CD28 antibodies) or with a combi-
nation of PMA and ionomycin. [3H]thymidine incorporation was measured 
by   scintillation counting. *, significantly different than Meg2 /  responses 
as determined by ANOVA with post hoc Sheffe test. (B) Lymph node–
derived T lymphocyte proliferation in response to agonist stimulation as 
assessed by [3H]thymidine uptake. *, significantly different than Meg2 /  
responses as determined by ANOVA with post hoc Sheffe test. (C) IL-2 
production in Meg2 /  and Meg2 /  T lymphocytes as assessed by ELISA. 
*, significantly different than Meg2 /  responses as determined by ANOVA. 
(D) Surface expression of IL-2 receptors (CD25) by Meg2 /  and Meg2 /  
T lymphocytes as assessed by flow cytometry. (E) IL-2 rescue of Meg2 /  
lymphocytes. Proliferation of Meg2 /  and Meg2 /  T lymphocytes in 
response to agonist stimulation without or with the addition of 50 U/ml 
exogenous IL-2 as assessed by [3H]thymidine uptake. *, significantly different 
than Meg2 /  lymphocytes without IL-2 rescue as determined by ANOVA. 
(F) Intracellular IL-2 production in Meg2 /  and Meg2 /  T lymphocytes 
as assessed by flow cytometry.PTP-MEG2 MODULATES SECRETORY VESICLE FUNCTION | Wang et al. 1594
express a variety of SNAREs, of which SNAP-23, VAMP-2,
and syntaxin-4 and syntaxin-6 appear to be involved in exo-
cytosis of granule contents (38, 39). Unexpectedly, the func-
tion of Meg2 /  neutrophils and macrophages was relatively
preserved, indicating that there must be cell-specific effects of
the regulation of NSF by MEG2 that remain to be clarified.
This is the subject of our current investigations.
Our studies clearly indicate the importance of MEG2 in
neural tube and cranial-facial development, but the molecu-
lar mechanisms remain unknown. In murine models of neu-
ral tube closure defects, various genetic mutations result in
an array of defects, including exencephaly, anecephaly, ra-
chischsis, and spina bifida, each reflecting the failure of ele-
vation of specific zones of the neural folds. The most com-
mon neural tube closure defect is isolated exencephaly,
whereas the combination of exencephaly with a craniofacial
defect, such as occurs in the Meg2 /  mice, is much less
common (40–43). Meg2 /  embryos and pups demonstrate
exencephaly, encephaloceles, foreshortened snout, and mid-
line hemorrhages in the frontal and nasal regions, indicating
that the most rostral part of the neural tube (zones A and B,
closures 2 and 3) has failed to close (40, 44). Meningomyelo-
celes were also observed in some Meg2 /  embryos and
pups, indicating failure of closure of the caudal part of the
neural tube.
Distinct types of neural tube defects correlate with spe-
cific genetic mutations in mice, implying spatial and tempo-
ral heterogeneity of molecular mechanisms regulating the el-
evation of neural folds. These include convergent extension
of the neural plate (45), elevation and apposition of the neu-
ral folds (46), and fusion of the neural tube folds (47). Dis-
crete cellular events are required for the successful closure of
cranial neural folds compared with spinal folds. For example,
expansion of the cranial mesenchyme (48, 49), contraction
of sub-apical actin microfilaments (50), and neural crest mi-
gration are considered to be important in the transition from
biconvex to biconcave neural plate morphology (51, 52) and
essential to cranial neural tube closure. Additionally, defects
in apoptosis and proliferation of neuroepithelium may also
contribute to failure of cranial neurulation (53). Investigation
of the role of MEG2 in these specific events is a focus of our
current investigations.
The cranial malformations and midline hemorrhages ob-
served in Meg2 /  mice are reminiscent of the phenotype
observed in mice with conditional deletion of PDGFR 
(Wnt1 Cre  PDGFR  neural crest cells) in cranial and car-
diac neural crest cells (54). However, in contrast to Meg2 / 
mice, the PDGFR   neural crest cell conditional mutant
mice demonstrate cardiovascular defects likely related to the
loss of essential PDGFR  functions in cardiac neural crest
cells. During murine embryogenesis, the cranial neural crest
cells differentiate into bone, cartilage, cranial ganglia, con-
nective tissue of the head and neck, odontoblasts, and cran-
iofacial mesenchyme (55). They also differentiate into peri-
cytes and smooth muscle cells of all blood vessels of the face
and forebrain (56, 57). Various genetic mutations affecting
processes in cranial neural crest cells in mice result in facial
malformations and exencephaly (51, 58). We speculate that
the craniofacial malformations, midline hemorrhages, and
Figure 7. Absence of secretory vesicles in Meg2 /  lymphocytes. 
(A) Electron microscopic analysis of vesicles in Meg2 /  and Meg2 /  
splenocytes, thymocytes, and lymph node cells. Cells are from spleen (a and i), 
thymus (b–d, g, and h), and lymph node (e, f, j, and k). (a–f) Meg2 /  lym-
phocytes. The arrows indicate typical dense core secretory vesicles that are 
present in normal numbers. (g and h–k) Meg2 /  lymphocytes. Note the 
near complete absence of dense core secretory vesicles and the presence 
of nonmembrane-bound collections of electron dense particles with a 
cluster-of-grapes appearance in Meg2 /  lymphocytes (i and k). (h) A 
Meg2 /  eosinophil with relatively normal appearance except that the 
vesicles are more elongated than normal. Magnifications are 15,000 (a, f, j, 
and k), 3,000 (b, c, h, and i), and 8,000 (d, e, and g). (k) The image is elec-
tronically magnified by a factor of 10. (B) Morphometric quantification of 
dense core vesicles from Meg2 /  and Meg2 /  T lymphocytes.JEM VOL. 202, December 5, 2005 1595
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bone defects in Meg2 /  mice are related to defective mi-
gration and/or differentiation of cranial neural crest cells.
In addition to the conspicuous developmental defects re-
lated to cranial neural crest cell function discussed above, we
have preliminary evidence that there are defects in other neu-
ral crest cell populations in Meg2 /  mice. Pigmentation de-
fects on the head, abdomen, and megacolon were observed
infrequently in Meg2 /  mice. Because these abnormalities
are associated with defects in trunk neural crest and enteric
neural crest cells, respectively, it is possible that MEG2 regu-
lates the development of these neural crest cells directly or in-
directly. However, given the low frequency of these defects,
it is possible that these are attributable to spontaneous muta-
tions in other loci and not related to MEG2 per se.
Published studies provide insights into certain devel-
opmentally regulated pathways involved in neurulation in
which MEG2 may play a role. Genetic mutations that result
in cranial neural tube closure defects are related to cell prolif-
eration, gap junction formation (59), organization of the
actin cytoskeleton (60), transcription factors such as Pax3
(61), and DNA methylation (62). As a tyrosine phosphatase,
MEG2 may affect neurulation and cranial structure forma-
tion through regulation of the phosphorylation state of sig-
naling proteins involved in these pathways. Given the im-
portance of MEG2 in secretory vesicle biogenesis and secretion,
we speculate that defective secretion of growth factors or
embryonic chemotaxins in the Meg2 /  cells might result in
aberrant migration and function of neural crest cells. In this
regard, signaling pathways involving PDGFR , FGF8, Wnt1,
ET-1, and TGF-  signaling (63–66) that are known to be
important in the regulation of craniofacial development are
potential pathways that might be regulated by MEG2.
Our observations that Meg2 /  mice display cranial and
dorsal hemorrhages suggest a role for this PTP in certain as-
pects of vascular development. As MEG2 is expressed by en-
dothelial cells (5), it is possible that the hemorrhages reflect
abnormal embryonic vascular development and/or integrity
related to faulty endothelial cell migration. This defective
vascular development would be compounded by the defec-
tive platelet function observed in these mice. Additionally,
the areas of hemorrhagic cerebral infarction might be ac-
counted for by a combination of endothelial dysfunction
leading to abnormal vascular development in association
with defective platelet function.
In summary, our studies demonstrate that MEG2 plays a
crucial role in neural tube, craniofacial, and bone develop-
ment as well as in platelet and lymphocyte activation. One of
the primary functions of MEG2 appears to be the control
of agonist-induced secretory (exocytic) processes, including
secretory vesicle genesis, maturation, and membrane fusion.
MATERIALS AND METHODS
All antibodies were obtained from BD Biosciences unless otherwise speci-
fied. Monoclonal hamster anti–mouse CD3  was produced by the 145-
2C11 hybridoma (Ontario Cancer Institute). PMA, ionomycin, and murine
IL-2 were from Sigma-Aldrich, and rabbit anti–hamster and anti–mouse
IgG antibodies and Cy5-conjugated streptavidin were from Jackson Immu-
noResearch Laboratories.
Targeted disruption of the murine Meg2 gene. All animal studies
were approved by the Institutional Review Boards of the University of Tor-
onto. A mouse 129/SvJ BAC genomic library was screened for Meg2, and a
clone containing the full-length Meg2 gene was isolated and sequenced us-
ing fluorescence dideoxy sequencing. In the targeting vector, a 4.2-kb DNA
fragment encompassing exons 10, 11, 12, and part of exon 13 was deleted
and replaced by a neomycin-resistance marker and cloned into a targeting
vector (pPNTLoxP). The linearized targeting vector was electroporated into
129/SvJ and R1 ES cells. Two independent heterozygous ES cell clones
were expanded and used to generate chimeric mice by blastocyst injection,
and the mutant animals were bred to a C57BL/6J background for nine gen-
erations. Genotyping was performed by Southern blotting (Fig. 1 E) or by
multiplex PCR (Fig. 1 D). For Southern analysis, genomic DNA was di-
gested with RcaI or StuI and hybridized with 3  and 5  probes, respectively.
The 5  probe corresponded to a 194-bp fragment amplified by PCR with
primer 5  probe-5 and 5  probe-6 (5 -AAAGACCTCCCCCCT-3  and 5 -
CCCAAATTCCAAACTGT-3 ), and the 3  probe corresponded to a
DNA fragment amplified by PCR from the murine genomic DNA with
primer PRM1 and PRM2 (5 -TAAACTAACATTGAGCCCTT-3  and
5 -TTCCAGTACATCCAGCAGT-3 ). Primers for multiplex PCR analy-
sis were 5 -TAGAGCTTGCGGAACCCTTA-3 , 5 -CTGGACACT-
GCTGAGCCTAT-3 , and 5 -AGTCTCCAAAGCACCATTCC-3 . The
PCR parameters are: denaturation at 95 C for 5 min, 35 cycles at 95 C for
30 s, 60 C for 30 s, and 72 C for 3 min.
RNA extraction and northern hybridization. Mouse Northern Blot
MTN1 and MTN2 (CLONTECH Laboratories, Inc.) and FirstChoice
Northern Mouse Blot I (Ambion) were hybridized with a 33P random– or
digoxigenin-labeled Meg2 cDNA probe. The latter probes were made with
the StripEZ PCR Kit (Ambion) and digoxigenin-11-dUTP (Roche Applied
Science). The blots were detected with a DIG luminescent detection Kit
(Roche Applied Science). PolyA  RNA was extracted from mouse embryos
at day E15 with the Micro PolyA Pure Kit (Ambion). Equal amounts of
PolyA  RNA were loaded, separated by electrophoresis, transferred to a pos-
itively charged nylon membrane (Roche Applied Science), and hybridized
with a digoxigenin-labeled mouse Meg2 cDNA probe and then reprobed
with a human  -actin RNA probe (Roche Applied Science).
Southern hybridization. Mouse genomic DNA was digested with the
specified restriction enzymes, electrophoretically separated, and hybridized
with digoxigenin-labeled DNA probes according to the manufacturer’s in-
structions (Roche Applied Sciences).
SDS PAGE and immunoblotting. SDS PAGE and immunoblotting
were performed as described previously (6).
Electron microscopy. Cells were fixed in 2% formaldehyde and 2% glu-
taraldehyde in 0.1 M cacodylate, pH 7.3, for 2 h at 4 C. Cells were washed
three times in the same buffer before a secondary fixation in 2% OsO4 (in
the same buffer) for 1 h at room temperature. Cells were washed an addi-
tional three times in the same buffer and then successively dehydrated in
ethanol, infused with propylene oxide, and embedded in Epon 812. Ul-
trathin sections were obtained using the Reichert-Jung microtome, double
stained with uranyl-acetate and lead citrate. Specimens were examined us-
ing a Hitachi-600 electron microscope at 75 kV with magnifications rang-
ing from 8,000 to 100,000.
Hematopoietic cell transplantation. Livers from day E15.5 Meg2 / ,
Meg / , and Meg2 /  embryos were genotyped and used to repopulate le-
thally irradiated (9.5 Gy) syngeneic Rag2 /  recipients. Fetal livers were dis-PTP-MEG2 MODULATES SECRETORY VESICLE FUNCTION | Wang et al. 1596
aggregated in Opi-MEM-1 medium. Irradiated C57B/6 or Rag2 /  mice
were injected via tail vein with a cell suspension containing 107 cells. The re-
constituted mice were kept in a pathogen-free environment, fed with antibi-
otic-treated water, and used between 8 and 10 wk after transplantation.
Flow cytometry. Flow cytometry was conducted as described previously
(67) using a FACScan flow cytometer with CELLQuest software (Becton
Dickinson).
Lymphocyte stimulation. Lymphocyte proliferation was assessed using
single cell suspensions prepared from thymuses, lymph nodes, and spleens of
age-matched Meg2 /  and Meg2 /  (C57BL/6) hematopoietic stem cell–
reconstituted Rag2 /  mice. Thymocytes and lymph node cells were cul-
tured for 48 h in culture medium alone or in the presence of either 0–25
 g/ml of plate-bound or 2  g/ml of soluble anti-CD3  antibody with or
without 0.2  g/ml anti-CD28 antibody or with 1  g/ml of soluble anti-
CD3 antibody plus 5 ng/ml PMA, 1  g/ml Con A, or 5  g/ml PMA plus
250 ng/ml ionomycin or 1  g/ml of soluble anti-CD3 antibody. Cultured
cells were pulsed with 1  Ci/well [3H]thymidine for 16 h before terminat-
ing the incubation. Incorporated radioactivity was measured using an auto-
mated   scintillation counter.
Cytokine analysis. IL-2 levels in cell supernatants were quantified by
ELISA (Genzyme). Levels of other cytokines were quantified using a multi-
plex fluorescent bead binding assay (LINCOplex; LINCO Research) and an-
alyzed using a Luminex 100 analyzer. Intracellular IL-2 levels were assessed by
flow cytometry on saponin-permeabilized cells as described previously (67).
Platelet isolation and aggregation. Hematopoietic progenitor cell–
transplanted mice were anesthetized and bled from the retro-orbital plexus
using a heparin-coated glass capillary tube containing 3.8% sodium citrate.
Platelet-rich plasma was washed twice with Pipes buffer (pH 7.0, 5 mM
Pipes, 137 mM NaCl, 4 mM KCl, 0.1% glucose). Platelet aggregation was
performed using a Chrono-Log aggregometer (Chrono-Log Corporation)
as described previously (68). Aggregation was induced by 20  M ADP
(Sigma-Aldrich). The same experiments were also performed with washed
platelets (2   108 platelets/ml) treated with 1 U/ml thrombin (Sigma-
Aldrich) at 1,000 rpm. The washed aggregates from each sample were visu-
alized with an inverted microscope (32X, 0.4NA; Zeiss Axiovert 135; Carl
Zeiss MicroImaging, Inc.), and images were captured with a digital camera
(DP70; Olympus).
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